| Literature DB >> 34025396 |
Feng Xie1, Yuan-Yuan Wu1, Guang-Jing Duan1, Bin Wang1, Feng Gao1, Pei-Feng Wei1, Lin Chen1, A-Ping Liu1, Min Li1.
Abstract
Dried ginger-aconite decoction (DAD) is a traditional Chinese medicine (TCM) formula that has been extensively used in the treatment of myocardial ischemia reperfusion injury (MI/RI). However, its specific mechanism against MI/RI has not been reported yet. Therefore, this paper studies the potential active components and mechanism of DAD against MI/RI based on network pharmacology and experimental verification. Sixteen active components of DAD were screened according to oral bioavailability and drug similarity indices. Through Cytoscape 3.7.0, a component-target network diagram was drawn, and potential active components of DAD against MI/RI were determined. Protein-protein interaction (PPI) and compound-target-pathway (C-T-P) networks were established through the software to discover the biological processes, core targets and core pathways of DAD against MI/RI. High Performance Liquid Chromatography (HPLC) analysis identified the presence of potentially active core components for network pharmacological prediction in DAD. It was found that DAD might have played a therapeutic role in anti-MI/RI by activating the PI3K/Akt/GSK-3β signaling pathway in order to reduce mitochondrial hypoxia injury and myocardial cell apoptosis. The network pharmacological prediction was validated by Hypoxia/reoxygenation(H/R) model in vitro and ligation model of the ligation of the left anterior descending branch in vivo. It was verified that DAD had activated PI3K/AKT/GSK-3β to reduce myocardial apoptosis and play a therapeutic function in MI/RI.Entities:
Keywords: dried ginger-aconite decoction; energy metabolism; myocardial ischemia reperfusion injury; network pharmacology; tcm
Year: 2021 PMID: 34025396 PMCID: PMC8135102 DOI: 10.3389/fphar.2021.609702
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Information on the 16 active compounds in the DAD.
| Herbal name | TCMSP ID | Compound | OB | DL |
|---|---|---|---|---|
| Aconite | MOL002395 | Deoxyandrographolide | 56.3 | 0.31 |
| Aconite | MOL002398 | Karanjin | 69.56 | 0.34 |
| Aconite | MOL002424 | aconitine | 7.87 | 0.23 |
| Aconite | MOL000538 | hypaconitine | 31.39 | 0.26 |
| Aconite | MOL002089 | mesaconitin | 8.7 | 0.25 |
| Aconite | MOL002388 | Delphin_qt | 57.76 | 0.28 |
| Aconite | MOL002392 | Deltoin | 46.69 | 0.37 |
| Dried ginger | MOL002467 | 6-gingerol | 35.64 | 0.16 |
| Dried ginger | MOL002459 | 10-gingerol | 19.14 | 0.28 |
| Dried ginger | MOL002495 | 6-shogaol | 31 | 0.14 |
| Dried ginger | MOL002516 | zingerone | 25.23 | 0.05 |
| Dried ginger | MOL000359 | sitosterol | 36.91 | 0.75 |
| Dried ginger | MOL002464 | 1-Monolinolein | 37.18 | 0.3 |
| Dried ginger | MOL002501 | [(1S)-3-[(E)-but-2-enyl]-2-methyl-4-oxo-1-cyclopent-2-enyl] (1R,3R)-3-[(E)-3-methoxy-2-methyl-3-oxoprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylate | 62.86 | 0.3 |
| Dried ginger | MOL002514 | Sexangularetin | 35.64 | 0.16 |
| Dried ginger | MOL000358 | beta-sitosterol | 36.91 | 0.75 |
FIGURE 1The networks of dried ginger and aconite decoction anti-MI/RI. (A) The compound-target network of DAD. The red nodes represent active compounds and the green nodes represent targets. The target surrounding the active components are proportional to their degree. (B) Overlap of DAD and MI/RI targets. The blue circles represent DAD targets and the yellow circles represent MI/RI targets. The shaded area is the target of DAD anti-MI/RI. (C) The protein-protein interaction network of protein targets obtained from STRING database and constructed by Cytoscape. The colors of the nodes are illustrated from blue to yellow to orange in descending order of degree values.
Targes information of DAD anti-MI/RI.
| Target name | Full name of the target | Uniprot ID |
|---|---|---|
| MAPK3 | Mitogen-activated protein kinase 3 | P27361 |
| CYP2C9 | Cytochrome P450 2C9 | P11712 |
| CYP2C8 | Cytochrome P450 2C8 | P10632 |
| CYP3A4 | Cytochrome P450 3A4 | P08684 |
| ARNTL | Aryl hydrocarbon receptor nuclear translocator-like protein 1 | O00327 |
| CD36 | Platelet glycoprotein 4 | P16671 |
| GATA4 | Transcription factor GATA-4 | P43694 |
| ITGA2B | Integrin alpha-IIb | P08514 |
| ITGB3 | Integrin beta-3 | P05106 |
| MTOR | Serine/threonine-protein kinase mtor | P42345 |
| OLR1 | Ox-LDL receptor 1 | P78380 |
| S100B | Protein S100-B | P04271 |
| TNF | Tumor necrosis factor | P01375 |
| BAX | Apoptosis regulator BAX | Q07812 |
| BCL2 | Apoptosis regulator Bcl-2 | P10415 |
| BDNF | BDNF | P23560 |
| CASP3 | Caspase-3 | P42574 |
| MAPK1 | Mitogen-activated protein kinase 1 | P28482 |
| CHAT | SH2 domain-containing protein 3C | Q8N5H7 |
| CHRNA5 | Neuronal acetylcholine receptor subunit alpha-5 | P30532 |
| IL1B | Interleukin-1 beta | P01584 |
| IL6 | Interleukin-6 | P05231 |
| NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 |
| TP53 | Cellular tumor antigen p53 | P04637 |
| TRPA1 | Transient receptor potential cation channel subfamily a member 1 | O75762 |
| ABCB1 | ATP-dependent translocase ABCB1 | P08183 |
| CYP1A2 | Cytochrome P450 1A2, EC 1.14.14.1 | P05177 |
| GSK3B | Glycogen synthase kinase-3 beta, GSK-3 beta | P49841 |
| CCND1 | G1/S-specific cyclin-D1 | P24385 |
| PPARG | PPAR-gamma | P37231 |
| PTGS2 | Prostaglandin G/H synthase 2 | P35354 |
| BIRC5 | Baculoviral IAP repeat-containing protein 5 | O15392 |
| GDF15 | Growth/differentiation factor 15 | Q99988 |
| CASP8 | Caspase-8 | Q14790 |
| NOS2 | Nitric oxide synthase, inducible | P35228 |
| CAT | Catalase | P04040 |
| MMP2 | 72 kDa type IV collagenases | P08253 |
| ADIPOQ | Adiponectin | Q15848 |
| MMP9 | Matrix metalloproteinase-9 | P14780 |
| MPO | Myeloperoxidase | P05164 |
| PARP1 | Poly [ADP-ribose] polymerase 1 | P09874 |
| SOD1 | Superoxide dismutase [Cu-Zn] | P00441 |
| SOD2 | Superoxide dismutase [Mn], mitochondrial | P04179 |
| AKT1 | RAC-alpha serine/threonine-protein kinase | P31749 |
| BECN1 | Beclin-1 | Q14457 |
| FAS | Tumor necrosis factor receptor superfamily member 6 | P25445 |
| FN1 | Fibronectin | P02751 |
| GHRL | Appetite-regulating hormone | Q9UBU3 |
| HIF1A | Hypoxia-inducible factor 1-alpha | Q16665 |
| NFKBIA | NF-kappa-B inhibitor alpha | P25963 |
| PRKCE | Protein kinase C epsilon type | Q02156 |
| RPS6KB1 | Ribosomal protein S6 kinase beta-1 | P23443 |
| NFE2L2 | Nuclear factor erythroid 2-related factor2 | Q16236 |
| HMOX1 | Heme oxygenase 1 | P09601 |
| DDIT3 | DNA damage-inducible transcript 3 protein | P35638 |
| GCLC | Glutamate--cysteine ligase catalytic subunit | P48506 |
| FABP4 | Fatty acid-binding protein | P15090 |
| GCLM | Glutamate--cysteine ligase regulatory subunit | P48507 |
| BCL2L1 | Bcl-2-like protein 1 | Q07817 |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme a reductase | P00347 |
| IFNG | Interferon gamma | P01579 |
| LCAT | Phosphatidylcholine-sterol acyltransferase | P04180 |
| LPL | Lipoprotein lipas | P06858 |
| TGFB1 | Transforming growth factor beta-1 proprotein | P01137 |
| TLR4 | Toll-like receptor 4 | O00206 |
| PTGS1 | Prostaglandin G/H synthase 1 | P23219 |
| PIK3CG | PI3K-gamma | P48736 |
| F2 | Prothrombin | P00734 |
| SCN5A | Sodium channel protein type 5 subunit alpha | Q14524 |
| F10 | Coagulation factor X | P00742 |
| ACHE | Acetylcholinesterase, AChE, EC 3.1.1.7 | P22303 |
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
| DPP4 | Dipeptidyl peptidase 4 | P27487 |
| ESR1 | Estrogen receptor | P03372 |
| NR3C2 | Mineralocorticoid receptor | P08235 |
| CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 |
| PDE3A | cGMP-inhibited 3′,5′-cyclic phosphodiesterase A | Q14432 |
| HTR2A | 5-hydroxytryptamine receptor 2A | P28223 |
| SLC6A4 | Sodium-dependent serotonin transporter | P31645 |
| PON1 | Serum paraoxonase/arylesterase 1 | P27169 |
FIGURE 2(A) The gene ontology (GO) enrichment analysis for key targets. (B) The KEGG pathway enrichment analysis of key targets. (C) The compound-target-pathway network constructed by Cytoscape. The blue nodes represent active components in DAD, the red nodes represent putative targets, the green nodes represent the signaling pathways. Node’s size is proportional to their degree. (D) PI3K/ Akt signaling pathway network (PI3K/Akt signaling pathway network is derived from https://www.cellsignal.cn/pathways/pathways-akt-signaling)
FIGURE 3Effects of dried ginger-aconite decoction (DAD) on survival rate and biochemical parameters of H9C2 cells damaged by H/R. (A) Effect on the survival rate of H9C2 cells. (B) Effect on oxidative stress factors MDA, SOD. (C) The effect on the activity of ATPase. Data were presented as mean standard deviation (SD). #p < 0.05, ##p < 0.01 vs. control group. *p < 0.05, **p < 0.01 vs. H/R group.
FIGURE 4Effects of dried ginger-aconite decoction (DAD) on apoptosis rate and Bax/Bcl-2 expression of H9C2 cells after H/R injury. (A) The effect on apoptosis rate. (B) The effect on the expression of Bax/Bcl-2. Data were presented as mean standard deviation (SD) of three independent experiments. #p < 0.05, ##p < 0.01 vs. control group. *p < 0.05, **p < 0.01 vs. H/R group.
FIGURE 5Changes of electrocardiogram in MI/RI rats and effects dried ginger-aconite decoction (DAD) on myocardial infarction area in MI/RI rats. (A) After modeling, ECG changes in Sham group, MI/RI group, CDDP group and DAD (1.4 g/kg, 2.8 g/kg, 5.6 g/kg) groups. (B) Effects on infarction range reduction of I/R injured rats. Data were presented as mean standard deviation (SD). # p < 0.05, ## p < 0.01 vs. sham group. *p < 0.05, **p < 0.01 vs. MI/RI group.
FIGURE 6Representative myocardial tissue histopathological sections on the effects of dried ginger-aconite decoction on myocardial infarction size in MI/RI rats (200×). Myocardial tissue injury was assessed by hematoxylin-eosin (H&E) staining.
FIGURE 7Effects of dried ginger-aconite decoction (DAD) on apoptosis of myocardial cells in MI/RI rats. Apoptosis of cardiomyocytes (green) and DAPI (nuclei Blue). Representative images were shown, and the scale bar indicated 20 µm. The percent of apoptosis cells were calculated for statistical analysis. Data were presented as mean standard deviation (SD). # p < 0.05, ## p < 0.01 vs. sham group. *p < 0.05, **p < 0.01 vs. MI/RI group.
FIGURE 8Effects of dried ginger-aconite decoction (DAD) on biochemical indices and MPTP conversion pores in MI/RI rats. (A) Effects on activities of myocardial enzymes CK, and LDH. (B) Effects on mitochondrial transformation pore MPTP. (C) Effect on oxidative stress factors MDA, and GSH-Px. Data were presented as mean standard deviation (SD). #p < 0.05, ##p < 0.01 vs. sham group. *p < 0.05, **p < 0.01 vs. MI/RI group.
FIGURE 9Experimental validation of key signaling pathways and mitochondrial key targets in vivo. Dried ginger-aconite decoction(DAD) activates the PI3k/Akt/GSK-3β signaling pathway and inhibits the expression of Cyt-C and CASP9. Data were presented as mean standard deviation (SD) of three independent experiments. # p < 0.05, ## p < 0.01 vs. sham group. *p < 0.05, **p < 0.01 vs. MI/RI group.